THE TALK OF THE TOWN
There is much hyperbole these days about the promise that our accomplishments in genome sequencing hold, and that they will herald a revolution in medicine by bringing about unheard progress in our ability to custom-tailor medical care to individual patients. People assert, in rather vague terms, an up-and-coming future of detailed understanding of currently unpredictable and perplexing differences in patients' response to medical treatment, based on the deciphering of their 'genetic background' that somehow is supposed to influence the medicine's effects.
How much off all this is true? If we assume, reasonably, that all common complex diseases-ie the health problems that are the main contributors to public and private health spendingoccur as a complex interaction between inborn predispositions and susceptibilities and external, environmental factors, then clearly a better, more fundamental understanding of these genetic predispositions is essential for any future progress in health care. Current progress in molecular biology and genetics does indeed provide us with the prerequisite tools to reach this more refined understanding. However, the recognized complexity of the gene-gene and geneenvironment interactions involved will at the same time assure thatdespite the 'completion' of the human genome sequencing effort-the rate of progress will not increase exponentially, although our newly-found ability to track biology down to its most basic, molecular level would perhaps qualify as some sort of paradigm shift: for the first time, within the epistemologic constraints of biomedical reasoning, we are able to determine cause rather than association.
NATURE AND NURTURE
If we hold that the interplay between nature and nurture, between an organism's internal properties and the environment it is exposed to, provides the fundamental duality that governs all expression of life, then clearly, the differential responses to the same medicine-in this case the environmental factor-we observe from one patient to another will be related at least in part to differences in these patients' 'blueprint' (barring other logical explanations pertaining to the 'environmental factor', such as noncompliance or co-administration of other medicines). Indeed, there is reason to believe that drugs, among all the environmental factors, may be most likely to 'interact' specifically and selectively with the genetic properties of a given individual, because their potency as environmental agents falls into a range that is between very weak and very strong environmental modulators. Very potent environmental factors affect life in a way that overpowers the organism's ability to respond in a differentiated, modulating fashion, based on its innate properties. Thus, an identical major trauma would be expected to show little differentiation in (immediate) outcome from one victim to another. On the other extreme of the spectrum, very mild environmental factors that do not reach the threshold of affecting phenotype at all, or do so only barely, are less likely to show much differentiation in the (immediate) elicited response. In contrast, medical-use compounds, as 'potion or poison' pitched in a very critical position, and thus potentially converted from one to the other based on a patient's innate, individual biological makeup, as it affects the interaction with a drug, would therefore be predicted to show particularly high sensitivity to the interaction with otherwise inapparent underlying characteristics.
THREE DIFFERENT SCENARIOS
Suppose a drug is found to have variable efficacy among patients receiving it. Once the most common causes for observed differences in the efficacy of a drug have been excluded, such as non-adherence to the physician-prescribed regimen or drug-drug interactions, we are left with three conceptually very different explanations that are commonly combined indiscriminately under the term 'pharmacogenetics'. They relate, on the one hand, to differential pharmacokinetics, due to inter-individual differences in absorption, distribution, metabolism or excretion of the drug, and on the other hand to differential pharmacodynamics, due to two quite distinctly different conceptual scenarios that relate to the two principal mechanisms by which drugs act when given for any particular disorder: etiology-specific and palliative. The former relates to drugs that work by targeting, and mitigating or correcting the actual cause of the disease or one of its etiologically contributing elements. In contrast, palliative drugs modulate disease-pheno-type-relevant pathways that are not dysfunctional but can be used to counterbalance the effect of a diseasecausing, dysfunctional pathway, without directly addressing the underlying cause or etiological contribution. Since a causative treatment will only work if the mechanism it addresses is indeed contributing to the patient's disease, such a treatment may be ineffective if that mechanism is not operative. There is general agreement today that any of the major clinical diagnoses, such as diabetes or cancer, are comprised of a number of etiologically (ie at the molecular level) distinct subcategories. In the case of an etiologically acting drug this implies that it will only be appropriate in a fraction of the patients who carry the clinical diagnosis; namely in those in whom the (dominant) molecular etiology matches the mechanism of the drug given. Thus, unrecognized and undiagnosed disease heterogeneity at the molecular level provides an important explanation for differential drug response and likely represents a substantial fraction of what is today somewhat indiscriminately called pharmacogenetics. On the other hand, in the case of a drug that works palliatively, inter-individual differences in the activity of the targeted pathways (and thus in the relative disease-counterbalancing effect of inhibiting or enhancing them) or molecular variations in the structure of the drug's biological target that affect the target's response to treatment, provide a second, conceptually different explanation for differential drug response based on pharmacodynamics. Here we are faced with disease-etiology-unrelated, interindividual variability as the root cause for differential drug response.
AT TIMES, JUST ANOTHER WORD FOR DIFFERENTIAL DIAGNOSIS
Thus, the 'practice' of pharmacogenetics will, in many instances, be marked by progress along the very same path that has been the main avenue of medical progress ever since Paracelsus: differential diagnosis. An increasingly sophisticated and precise differential diagnosis of disease, arising from a deeper, more differentiated under-
The Pharmacogenomics Journal standing of pathology at the molecular level, will foster these advances. Therefore, the sequence of events commonly expected as characteristic for a 'pharmacogenetic scenario'-namely, exposing patients to the drug, recognizing differential response, discovering a marker predicting this response, and creating a diagnostic product to be co-marketed with the drug henceforth-is likely to be turned on its head. Rather, we will search for a new drug specifically, and a priori, based on a new diagnosis (ie a newlyfound ability to diagnose a molecular sub-entity of a previously more encompassing, imprecise clinical disease definition). Thus, pharmacogenetics will not be so much about finding the 'right medicine for the right patient', but about finding the 'right medicine for the right disease', as we have aspired to all along. This is, in fact, good news: the conventional 'pharmacogenetic scenario' would unvariably present major challenges from both a regulatory and a business development and marketing standpoint, as it will confront the development team with a critical change in the drug's profile at a very late point in the development process. In addition, the timely development of an approvable diagnostic product in this situation is difficult at best, and its marketing as an 'add-on' to the drug a less than attractive proposition to diagnostics business.
Where differential efficacy/safety status is indeed a manifestation of the inherent molecular-etiological diversity of common diseases, there is an opportunity to 'front-load' the critical information and create the moleculardiagnosis-specific medicine in a far more straightforward and logical way. The sequence of events in this case would likely involve, first, the development of an in vitro diagnostic test as a stand-alone product that sells on its own merits in allowing the physician to correctly establish a state-of-the-art diagnosis of the molecular subtype of the patient's disease-even in the absence of any as yet developed pharmaceuticals (if for no other reason than the one that developing a drug takes two-to three-times longer than developing a diagnostic). The marketing of such a tool is likely justifiable by the advantages the thus obtained knowledge provides in terms of the likely response-or lack thereof-to existing medicines, and the potential applicability of non-drug treatment modalities such as specific changes in diet or lifestyle. If and when a medicine tailored to the particular differential diagnosis becomes available, the development process, based on the by then existing body of knowledge about the nature of the molecular disease (sub)-entity will allow a prospectively planned, much more systematic approach towards clinical and business development, with a commensurate greater chance of actual success.
DIAGNOSIS AND TREATMENT ON EQUAL FOOTING FOR THE FIRST TIME
Another way to conceptually envision the scenario described above is to reflect on the one-if any-fundamental shift in the practice of medicine that we are likely to encounter as a consequence of the introduction of powerful molecular biology and genetic/genomic approaches into biomedical research: the shift from our current state-of-the-art clinical diagnoses, and definition of disease based primarily on clinical criteria, to an ultimately more meaningful molecular diagnosis and disease definition. This development will, at long last, join the longstanding disconnect between medicinal treatment-whose action has always occurred on the molecular level-and clinical disease diagnosis that describes pathology on a much less sophisticated, rather crude pathoanatomic or histological level. For the first time we will be able to match diagnosis and treatment at the same level, and thus meet recognized disease mechanisms with the functionally appropriate treatment in a controlled, rational fashion, rather than by the trial-and-error method we had at our disposal so far.
Practically speaking, some guesswork will remain, due to the nature of common complex disease. First, any and all diagnostic approaches will ultimately only provide a measure of probability, not of certainty, and we will see shades of gray rather than blacks and whites as a result of this. In addition, based on our current understanding of the polygenic and heterogeneous nature of these disorders, we will-even in an ideal world where we know about all possible susceptibility gene variants for a given disease and have treatments for them-only be able to exclude, in any given patient, those that do not appear to contribute to the disease, and therefore rule out certain treatments. We will, however, most likely find ourselves left with a small number-two to four, perhapsof potentially disease-contributing gene-variants whose relative contribution to the disease will be very difficult if not impossible to rank in any individual patient. Likely then, trial and error, but on a more limited and sub-selective basis, will still play a role.
WHOLE-GENOME PHARMACOGENETICS
The alternative scenario, where differential drug response and/or safety occurs with a 'palliative' drug, or despite having prescribed an 'etiologically applicable' medicine, poses, as discussed, much greater difficulty in planning and executing a development program, even if one were to find a marker/diagnostic that predicts the drug's efficacy/adverse events. In addition, there are considerable obstacles towards finding such a marker, unless it is one of the 'obvious' candidate genes implicated in the disease physiopathology or the treatment's mode of action. More often, it will likely be necessary to embark on an unbiased whole genome screen, using Single Nucleotide Polymorphisms (SNPs) as molecular flagpoles. Although there is much talk today about such projects, the obstacles that will have to be overcome on the technical, data-analysis, and cost levels are formidable. They will limit the deployment of such programs, at least for the foreseeable future, to select cases in which there are very solid indications for doing so, based on clinical data showing a near-categorical (eg bimodal) distribution of treatment outcomes. Even then, we may expect www.nature.com/tpj for every success-that will be owed to a favorably strong linkage-disequilibrium across considerable genomic distance in the relevant chromosomal region-to encounter as many or more failures, in cases where the culpable gene variant cannot be found due to the higher recombination rate or other characteristics of the stretch of genome that it is located on.
PHARMACOGENETIC TESTING FOR DRUG EFFICACY VS SAFETY
In principle, pharmacogenetic approaches may be useful both to raise efficacy and to avoid adverse events, by stratifying patient eligibility for a drug according to appropriate markers. In both cases clinical decisions and recommendations must be supported by data that have undergone rigorous biostatistical scrutiny. As the prerequisites and opportunities to acquire such data, and their application to clinical decision-making are quite different in the two cases, we expect the use of pharmacogenetics for enhanced efficacy to be much more common than for the avoidance of adverse events.
The likelihood that adequate data on efficacy in a subgroup may be generated is reasonably high, given the fact that unless the drug is viable in a sizeable number of patients it will probably not be developed for pharmacoeconomic reasons. Implementation of pharmacogenetic testing to stratify for efficacy, provided that safety in the non-responder group is not an issue, will primarily be a matter of physician preference and sophistication, and potentially of third-party payer directives, but is less likely to be a matter of regulatory mandate. Indeed, an argument can be made against depriving those from being eligible for the drug who carry the non-responder genotype, but who individually, of course, may respond to the drug with a certain, albeit lower probability. From a regulatory aspect, use of pharmacogenetics for efficacy, if adequate safety data exist, appears largely unproblematic-the worst-case scenario (a genotypically inappropriate patient receiving the drug) resulting in treatment without expected beneficial effect, but with no adverse consequences, ie much of what one would expect under conventional paradigms.
The utility and clinical application of pharmacogenetic approaches towards improving safety, in particular with regard to serious adverse events, will meet with much greater hurdles and is therefore expected as much less likely to become reality (except for the area of pharmacokinetics, where differential dosing based on genotype may be relatively straightforward; the trend, however, is to find compounds metabolized by pathways that show no such variance). The reasons are easy to see: first, in the event of serious adverse events associated with the use of a medicine, withdrawal/recall is usually based entirely on anecdotal evidence from a rather small number of cases-in accordance with medicine's first mandate 'primum non nocere'. If the sample size is insufficient to statistically demonstrate a significant association between drug exposure and event, it is most certainly insufficient to allow testing for genotype-phenotype correlations; all the more since the number of degrees of freedom applicable to the latter will be considerable, and the fraction of attributable risk shown to be associated with a given at-risk genotype would have to be very substantial for regulators to accept such data. Second, the very nature of safety issues raises the hurdles substantially because in this situation the worst-case scenarioadministration of the drug to the 'wrong' patient-will result in harm to the patient. Therefore, it is likely that the practical application of pharmacogenetics towards limiting an adverse event will be restricted to diseases with dire prognosis, where a high medical need exists, where the drug in question offers unique potential advantages, and where the side effect is both relatively common and tolerated in favor of the drug's beneficial effects, eg in areas like oncology or HIV/AIDS. In contrast, the proposed, conceptually highly attractive, routine deployment of pharmacogenetics as a generalized drug surveillance practice following the introduction of a new medicine faces the sobering biostatistical and regulatory considerations discussed; barriers that are unlikely to be overcome.
PHARMACOGEN-ETHICS
Arguments have been advanced that genotype determinations for pharmacogenetic characterization, in contrast to 'genetic' testing for primary disease risk assessment, are less likely to raise potentially sensitive issues with regard to patient confidentiality, the misuse of genotyping data or other nucleicacid-derived information, and the possibility of stigmatization. While this may be true when pharmacogenetic testing is compared to predictive genotyping for highly penetrant Mendelian disorders, it is not apparent why in common complex disorders predictors of primary disease risk would be any more sensitive in nature than predictors of likely treatment success. Indeed, two lines of reasoning may actually indicate an increased potential for ethical issues and complex confrontations among the various stakeholders to arise from pharmacogenetic data.
First, while access to genotyping and other nucleic acid-derived data related to disease susceptibility can be strictly limited, the very nature of pharmacogenetic data calls for a rather more liberal position regarding use, and thus dissemination of this information, if it is to serve its intended purpose, ie improving the patients' chance for successful treatment. Thus, the prescription of a drug that is limited to a group of patients with a particular genotype will, immediately by implication, disclose the receiving patient's genotype to the pharmacist, his apprentice, the person at the cash register, the insurance company's data entry clerk, the claims adjuster, and a host of additional personnel involved in health care administration and reimbursement. The only way to limit this almost public disclosure of this patient's genotype data would be if he or she were to sacrifice the benefits of the indicated treatment for the sake of data confidentiality.
Second, although difficult to predict in any given case, patients profiled to
The Pharmacogenomics Journal carry a high disease probability along with a high likelihood for treatment response may be viewed, from the standpoint of insurance risk (to focus on one of the commonly cited potential issues), as at par with patients displaying the opposite profile, ie a low risk to develop the disease, but a high likelihood not to respond to medical treatment in case the disease indeed occurs. For any given disease risk, patients less likely to respond to treatment would be seen as a more unfavorable insurance risk-depending on whether treatment non-responder status is associated with early mortality or with chronic illness: the latter case having much more far-reaching economic consequences. The pharmacogenetic profile may thus, under certain circumstances, even become a more important (financial) risk-assessment parameter than primary disease susceptibility, and would be expected-in as much as it represents one stone in the complex-disease mosaic-to be treated with similar weight, or lack thereof, as other genetic and environmental risk factors.
Evidently, the critical issue is not so much the sensitive nature of the information, or its dissemination, but the areas in which society sanctions the use of this information. Insurance companies will have little issue not having access to certain data, if they are all on a level competitive playing field based on applicable regulation. This implies, of course, that society as a whole endorses, in an act of solidarity with those destined to develop a certain disease, to share the burden of financial risk with them. In order to ensure this kind of social justice, there is an urgent need for the legal codification of societal values and morals regarding the proper and improper use of sensitive medical data in general. Such a legal framework will, in the end, ensure that information may legitimately be used in the patient's interest and to the patient's benefit, while any misuse to the individual's disadvantage will represent an unlawful activity. Obviously, generation and acquisition of personal medical information must always be contingent on the individual's free choice and consent, as must be all application of such data for specific purposes. As long as we trust our political decision processes to reflect societal consensus, and as long as such consensus reflects the principles of justice and equality, the resulting set of laws and principles should assert such proper use of medical information. Also, given the fact that in many parts of the world health insurance carriers still do not adjust rates according to smoking status, and that it is not very likely that genotypeassociated risk factors of the magnitude conferred by smoking will be demonstrated in the near term, if at all, the public concerns regarding these issues may possibly have been somewhat overemphasized.
CONCLUSION
Pharmacogenetics, in the various actual meanings of the term, will represent an important new avenue towards understanding disease pathology and drug action, and will offer new opportunities of stratifying patients to achieve optimal treatment success. As such, if viewed sine ira et studio and outside the hyperbole generated by media and stock markets, it represents a logical, consequent step in the history of medicine-evolution, rather than revolution. Its implementation will take time, and will not apply to all diseases and all treatments equally. If society finds ways to protect patients from misuse of this information, while allowing and protecting its unencumbered use for the patient's benefit, important progress in health care will be made.
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